TESARO, Inc. (TSRO) Given “Hold” Rating at Jefferies Group LLC

Jefferies Group LLC reiterated their hold rating on shares of TESARO, Inc. (NASDAQ:TSRO) in a research note issued to investors on Friday, November 3rd. They currently have a $124.00 price objective on the biopharmaceutical company’s stock.

Several other equities analysts have also recently issued reports on TSRO. Robert W. Baird restated a neutral rating and set a $140.00 target price (down previously from $155.00) on shares of TESARO in a research note on Thursday, August 10th. Morgan Stanley reissued an overweight rating and issued a $183.00 target price on shares of TESARO in a report on Thursday, August 10th. Credit Suisse Group set a $190.00 target price on shares of TESARO and gave the stock a buy rating in a report on Friday, August 18th. BidaskClub raised shares of TESARO from a strong sell rating to a sell rating in a report on Wednesday, August 23rd. Finally, SunTrust Banks, Inc. reaffirmed a buy rating and set a $235.00 price objective on shares of TESARO in a report on Sunday, August 20th. Two investment analysts have rated the stock with a sell rating, ten have assigned a hold rating, fourteen have assigned a buy rating and one has given a strong buy rating to the company. TESARO presently has an average rating of Buy and an average price target of $161.72.

Shares of TESARO (NASDAQ:TSRO) traded down $1.19 during trading on Friday, reaching $83.91. 708,346 shares of the company’s stock traded hands, compared to its average volume of 1,029,724. TESARO has a twelve month low of $83.35 and a twelve month high of $192.94. The company has a debt-to-equity ratio of 0.34, a current ratio of 4.73 and a quick ratio of 4.35.

TESARO (NASDAQ:TSRO) last announced its quarterly earnings data on Tuesday, November 7th. The biopharmaceutical company reported ($0.47) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($1.16) by $0.69. The firm had revenue of $142.77 million during the quarter, compared to analyst estimates of $130.57 million. TESARO had a negative net margin of 251.22% and a negative return on equity of 93.39%. The business’s quarterly revenue was up 740.3% on a year-over-year basis. During the same period in the previous year, the business posted ($1.72) EPS. equities research analysts predict that TESARO will post -8.16 earnings per share for the current fiscal year.

WARNING: “TESARO, Inc. (TSRO) Given “Hold” Rating at Jefferies Group LLC” was originally reported by BBNS and is owned by of BBNS. If you are viewing this news story on another website, it was stolen and republished in violation of US & international copyright & trademark laws. The correct version of this news story can be accessed at https://baseballnewssource.com/markets/tesaro-inc-tsro-receives-hold-rating-from-jefferies-group-llc/1755747.html.

In other news, VP Grant C. Bogle sold 14,167 shares of the company’s stock in a transaction on Friday, September 1st. The stock was sold at an average price of $135.00, for a total value of $1,912,545.00. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, VP Edward C. English sold 10,862 shares of the company’s stock in a transaction on Wednesday, September 6th. The shares were sold at an average price of $134.92, for a total value of $1,465,501.04. Following the completion of the transaction, the vice president now directly owns 6,258 shares in the company, valued at approximately $844,329.36. The disclosure for this sale can be found here. Insiders have sold 35,692 shares of company stock valued at $4,628,976 over the last quarter. 34.60% of the stock is owned by company insiders.

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Iguana Healthcare Management LLC lifted its stake in TESARO by 66.7% during the 3rd quarter. Iguana Healthcare Management LLC now owns 25,000 shares of the biopharmaceutical company’s stock worth $3,228,000 after acquiring an additional 10,000 shares in the last quarter. Neuberger Berman Group LLC lifted its stake in TESARO by 22.8% during the 3rd quarter. Neuberger Berman Group LLC now owns 153,540 shares of the biopharmaceutical company’s stock worth $19,822,000 after acquiring an additional 28,500 shares in the last quarter. Bamco Inc. NY lifted its stake in TESARO by 30.7% during the 3rd quarter. Bamco Inc. NY now owns 13,128 shares of the biopharmaceutical company’s stock worth $1,695,000 after acquiring an additional 3,087 shares in the last quarter. Perceptive Advisors LLC lifted its stake in TESARO by 8.1% during the 3rd quarter. Perceptive Advisors LLC now owns 388,651 shares of the biopharmaceutical company’s stock worth $50,175,000 after acquiring an additional 29,100 shares in the last quarter. Finally, Janus Henderson Group PLC raised its position in TESARO by 24.9% in the 3rd quarter. Janus Henderson Group PLC now owns 895,556 shares of the biopharmaceutical company’s stock valued at $115,616,000 after purchasing an additional 178,406 shares in the last quarter.

TESARO Company Profile

TESARO, Inc is an oncology-focused biopharmaceutical company. The Company operates through the business of developing and commercializing of oncology-focused therapeutics segment. It is developing oncology-related product candidates, including rolapitant, niraparib and the product candidates under its immuno-oncology platform.

Analyst Recommendations for TESARO (NASDAQ:TSRO)

Receive News & Ratings for TESARO Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TESARO Inc. and related companies with our FREE daily email newsletter.

 


Latest News

Jack Morris, Alan Trammel Voted by Modern Era Committee into Hall of Fame
Jack Morris, Alan Trammel Voted by Modern Era Committee into Hall of Fame
Yankees and Marlins Continue Stanton Trade Talks
Yankees and Marlins Continue Stanton Trade Talks
Marlins Making Moves, Trade Dee Gordon to Seattle
Marlins Making Moves, Trade Dee Gordon to Seattle
Report: Astros Dallas Keuchel Pitched With Injured Foot
Report: Astros Dallas Keuchel Pitched With Injured Foot
Angels Sign Former Prospect with Braves Kevin Maitan
Angels Sign Former Prospect with Braves Kevin Maitan
Shohei Ohtani Has Turned Down Red Sox and Yankees
Shohei Ohtani Has Turned Down Red Sox and Yankees


Leave a Reply

 
© 2006-2017 BBNS.